Healthcare Professionals
For US Patients
RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) logo, home

AI-generated image. Not an actual patient.

Senior woman hugging an elderly man from behind while relaxing on a sofaSenior woman hugging an elderly man from behind while relaxing on a sofa

RYBREVANT FASPRO
is approved for certain types of cancer

Learn more by selecting a type of cancer below:

Non–Small Cell
Lung Cancer

RYBREVANT FASPRO injections and RYBREVANT infusions are medicines used to treat non–small cell lung cancer (NSCLC) that has spread to other parts of the body (metastatic) or cannot be removed by surgery, and has certain abnormal EGFR gene(s):

  • in combination with LAZCLUZE® (lazertinib) as a first treatment
  • in combination with chemotherapy for people whose disease has worsened on or after treatment with an EGFR tyrosine kinase inhibitor (TKI)
  • in combination with chemotherapy as a first treatment
  • alone for people whose disease has worsened on or after platinum-based chemotherapy
NOW APPROVED
Head & Neck Squamous Cell Carcinoma

RYBREVANT FASPRO is used for adults with head and neck cancer that has spread to other parts of the body (metastatic) or has come back, whose disease has worsened on or after platinum-based chemotherapy and an anti–PD-(L)1 immunotherapy.

Not for use to treat people with oropharyngeal squamous cell carcinoma (OPSCC) that is human papillomavirus (HPV)-associated.

RYBREVANT FASPRO is approved based on treatment response and how long the response lasted. Continued approval may depend on future studies that confirm its benefits.

AI-generated image. Not an actual patient.

Once you and your doctor have decided that a RYBREVANT FASPRO–based treatment is right for you, sign up for:

Starting a new treatment can be overwhelming and you may still have questions. We are here to help.

Dedicated Care Navigator*

Cost Support

Additional Support & Community Connections

Want to learn more about available support?

Ready to get started?

The support and resources provided by J&J withMe and RYBREVANT withMe are not intended to provide medical advice, replace a treatment plan you receive from your doctor or nurse, or serve as a reason for you to start or stay on treatment.

*Currently available only for patients with NSCLC. Coming early 2027 for patients with HNSCC.

EGFR, epidermal growth factor receptor; HNSCC, head and neck squamous cell carcinoma; PD-(L)1, programmed cell death (ligand) protein 1.